A detailed history of Walleye Capital LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 8,500 shares of EXEL stock, worth $296,055. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,500
Holding current value
$296,055
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $63,354 - $79,626
2,885 New
2,885 $74,000
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $2.62 Million - $3.1 Million
-129,749 Reduced 69.27%
57,549 $1.37 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $2.91 Million - $3.65 Million
-151,348 Reduced 44.69%
187,298 $4.49 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $4.83 Million - $5.76 Million
253,449 Added 297.49%
338,646 $7.4 Million
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $1.55 Million - $1.74 Million
85,197 New
85,197 $1.63 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $667,670 - $948,278
42,581 Added 36.54%
159,124 $2.5 Million
Q2 2022

Aug 08, 2022

BUY
$17.44 - $23.16 $1.41 Million - $1.87 Million
80,618 Added 224.41%
116,543 $2.43 Million
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $313,794 - $417,717
18,426 Added 105.3%
35,925 $814,000
Q4 2021

Mar 03, 2022

BUY
$15.84 - $21.88 $277,184 - $382,878
17,499 New
17,499 $319,000
Q3 2021

Nov 15, 2021

SELL
$16.3 - $21.14 $216,969 - $281,394
-13,311 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$17.95 - $25.56 $329,741 - $469,537
-18,370 Reduced 57.98%
13,311 $243,000
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $650,410 - $798,994
31,681 New
31,681 $716,000
Q3 2019

Nov 14, 2019

SELL
$17.68 - $22.65 $200,668 - $257,077
-11,350 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $109,661 - $143,376
-5,793 Reduced 33.79%
11,350 $243,000
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $336,002 - $424,460
17,143 New
17,143 $408,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.